Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

and Crohn’s disease (CD). RELIEVE UCCD assessed duvakitug, a human IgG1-?2 monoclonal antibody targeting TL1A, for the treatment of moderate-to-severe inflammatory bowel disease (IBD). In the RELIEVE ...

Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.

A device used in South Jersey is a game-changer for people with inflammatory bowel disease as an alternative to invasive ...

Crohn's disease, a type of chronic inflammatory bowel disease (IBD), often causes scar-like tissue to build up in the ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

The companies said Tuesday that patients with ulcerative colitis who were treated with duvakitug achieved a higher rate of clinical remission compared with a placebo group. A group of patients with ...

Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...

Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, ...

As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...

Crohn disease location, particularly ileal predominance, is associated with specific treatment patterns, such as more biologic therapy.

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...